Hizentra delivered low rates of infection in a 12-month study with zero serious infections and an average of 2.76 overall infections per subject-year.
Serious bacterial infections are infections that could potentially require hospitalization, like bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
People taking Hizentra missed about 2 days of work or school per year due to infections (2.06 days per person per year on average in clinical studies).
The safety and efficacy of Hizentra have been established in patients age 2 and older.
In a 12-month study of people taking Hizentra, there were no serious side effects related to treatment.
Two subjects withdrew from the study due to non-serious side effects. Please see full Important Safety Information below, including boxed warning.
The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible.
The only SCIg that has been providing safe protection against infection since 2010.